Hemato-oncology
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
Young Hoon Park, Dae-Young Kim, Yeung-Chul Mun, Eun Kyung Cho, Jae Hoon Lee, Deog-Yeon Jo, Inho Kim, Sung-Soo Yoon, Seon Yang Park, Byoungkook Kim, Soo-Mee Bang, Hawk Kim, Young Joo Min, Jae Hoo Park, Jong Jin Seo, Hyung Nam Moon, Moon Hee Lee, Chul Soo Kim, Won Sik Lee, So Young Chong, Doyeun Oh, Dae Young Zang, Kyung Hee Lee, Myung Soo Hyun, Heung Sik Kim, Sung-Hyun Kim, Hyukchan Kwon, Hyo Jin Kim, Kyung Tae Park, Sung Hwa Bae, Hun Mo Ryoo, Jung Hye Choi, Myung-Ju Ahn, Hwi-Joong Yoon, Sung-Hyun Nam, Bong-Seog Kim, Chu-Myong Seong
Korean J Intern Med. 2022;37(4):841-850. Published online June 28, 2022
Background/Aims: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL).
Methods: We included 87 patients with newly diagnosed acute myeloid l..
|
|
Practice patterns of multidisciplinary team meetings in Korean cancer care and patient satisfaction with this approach
Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Seungtaek Lim, Bong-Seog Kim, Do Yeun Kim
Korean J Intern Med. 2020;35(1):205-214. Published online December 6, 2019
Background/Aims: The multidisciplinary team (MDT) approach is a cornerstone of clinical oncology. This study investigated the current state of MDT care, including patient satisfaction, in Korea.
Methods: We obtained the annual number of cancer patients who have received MDT care since 2014 from the..
|
|
Surrogate decision making of chemotherapy consent: do we really provide informed consent of chemotherapy for patients?
Jung Hye Kwon, Sun Kyung Baek, Bong-Seog Kim, Su-Jin Koh, Hee Kyung Ahn, Joo Han Lim, Chiyeon Lim, Do Yeun Kim
Korean J Intern Med. 2019;34(3):626-633. Published online May 31, 2018
Background/Aims: Despite increased demand for cancer patient’s to make their own decisions based on an adequate understanding of what is involved in chemotherapy, the primary signing agent and the reasons for surrogate signing have not been appropriately evaluated.
Methods: The ethics committee of..
|
|
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study
Jae Ho Byun, Joong Bae Ahn, Sun Young Kim, Jung Hun Kang, Dae Young Zang, Seok Yun Kang, Myoung Joo Kang, Byoung Yong Shim, Sun Kyung Baek, Bong-Seog Kim, Kyung Hee Lee, Soon Il Lee, Sang-Hee Cho, Byeong Seok Sohn, Samyong Kim, In Gyu Hwang, Eun Mi Nam, Bong-Gun Seo, Sang Cheul Oh, Myung-Ah Lee, Sang-Cheol Lee, Ji Hyung Hong, Young Suk Park
Korean J Intern Med. 2019;34(1):165-177. Published online November 28, 2017
Background/Aims: Colorectal cancer is associated with different anatomical, biological, and clinical characteristics. We determined the impact of the primary tumor location in patients with metastatic colorectal cancer (mCRC).
Methods: Demographic data and clinical information were collected from 1..
|
|
Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report
Sehe-Dong Lee, Hye-Jeong Kim, Seung-Jae Hwang, Yoon-Jung Kim, Seung-Hyun Nam, Bong-Seog Kim
Korean J Intern Med. 2007;22(2):109-112. Published online June 30, 2007
Hand-foot syndrome (HFS) is a well-known adverse event associated with capecitabine, a prodrug of 5-Fluorouracil (5-FU). HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progres..
|
|
Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
Seung Jae Hwang, Jong Won Park, Sehe Dong Lee, Gyong Jung Kim, Cheol Ho Sin, Seung-Hyun Nam, Bong-Seog Kim
Korean J Intern Med. 2006;21(4):252-255. Published online December 31, 2006
Gastric cancer patients with severe liver dysfunction secondary to hepatic metastases have limited treatment options. Most cytotoxic drugs have a narrow therapeutic index. Although both capecitabine and oxaliplatin have been well tolerated as single agents for patients with severe hepatic dysfunc..
|
|
Phase 2 Study to Topotecan and Cisplatin in Advanced Hepatocellular Carcinoma
Ga Young Lee, Bong-Seog Kim, Yeoung Tae Seo, Seong Ho Choi, Hye Jin Kim, Dong Seog Choi, Ji Young Ko, Soo Hyun Yang, M.D. and Jong Hoon Byun
Korean J Intern Med. 2003;18(2):104-108. Published online June 1, 2003
|
|
|